Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steffan T Nawrocki

Showing results (1-10 of 77) with videos related to

Pageof 8
Sort By:
Autophagy|January 25, 2017
Drain the lysosome: Development of the novel orally available autophagy inhibitor ROC-325Jennifer S Carew, Steffan T Nawrocki
Cancer Biology & Therapy|May 24, 2005
Velcade displays promising activity in primary effusion lymphoma cellsDavid McConkey, Steffan T Nawrocki, Robert Andtbacka
Cancers|October 21, 2020
Autophagy: New Insights into Its Roles in Cancer Progression and Drug ResistanceSteffan T Nawrocki, Wei Wang, Jennifer S Carew
Targeted Oncology|May 7, 2011
Mechanisms of mTOR inhibitor resistance in cancer therapyJennifer S Carew, Kevin R Kelly, Steffan T Nawrocki
Cancer Letters|May 9, 2008
Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapyJennifer S Carew, Francis J Giles, Steffan T Nawrocki
Cancers|May 13, 2020
Therapeutic Targeting of Autophagy for Renal Cell Carcinoma TherapyTrace M Jones, Jennifer S Carew, Steffan T Nawrocki
Autophagy|May 15, 2007
Modulating autophagy for therapeutic benefitJennifer S Carew, Steffan T Nawrocki, John L Cleveland
Cancer Management and Research|October 24, 2012
Autophagy as a target for cancer therapy: new developmentsJennifer S Carew, Kevin R Kelly, Steffan T Nawrocki
Expert Opinion on Investigational Drugs|July 18, 2012
MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapySteffan T Nawrocki, Patrick Griffin, Kevin R Kelly, et al.
Molecular Cancer Therapeutics|January 30, 2004
The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenograftsSteffan T Nawrocki, Bridget Sweeney-Gotsch, Ryan Takamori, et al.
Pageof 8

Showing results (1-10 of 77) with videos related to

Sort By:
Pageof 8
Autophagy|January 25, 2017
Drain the lysosome: Development of the novel orally available autophagy inhibitor ROC-325Jennifer S Carew, Steffan T Nawrocki
Cancer Biology & Therapy|May 24, 2005
Velcade displays promising activity in primary effusion lymphoma cellsDavid McConkey, Steffan T Nawrocki, Robert Andtbacka
Cancers|October 21, 2020
Autophagy: New Insights into Its Roles in Cancer Progression and Drug ResistanceSteffan T Nawrocki, Wei Wang, Jennifer S Carew
Targeted Oncology|May 7, 2011
Mechanisms of mTOR inhibitor resistance in cancer therapyJennifer S Carew, Kevin R Kelly, Steffan T Nawrocki
Cancer Letters|May 9, 2008
Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapyJennifer S Carew, Francis J Giles, Steffan T Nawrocki
Cancers|May 13, 2020
Therapeutic Targeting of Autophagy for Renal Cell Carcinoma TherapyTrace M Jones, Jennifer S Carew, Steffan T Nawrocki
Autophagy|May 15, 2007
Modulating autophagy for therapeutic benefitJennifer S Carew, Steffan T Nawrocki, John L Cleveland
Cancer Management and Research|October 24, 2012
Autophagy as a target for cancer therapy: new developmentsJennifer S Carew, Kevin R Kelly, Steffan T Nawrocki
Expert Opinion on Investigational Drugs|July 18, 2012
MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapySteffan T Nawrocki, Patrick Griffin, Kevin R Kelly, et al.
Molecular Cancer Therapeutics|January 30, 2004
The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenograftsSteffan T Nawrocki, Bridget Sweeney-Gotsch, Ryan Takamori, et al.
Pageof 8